From GlobeNewswire:

BioCryst Pharmaceuticals, Inc. has announced preliminary, unaudited ORLADEYO net revenue for the full year 2023 of $325 million, a 29 percent increase year-over-year. The company expects ORLADEYO net revenue to be between $380-$400 million in 2024 and is on trajectory for $1 billion in peak sales. Operating expenses are expected to remain flat in 2024 at $365-$375 million. The company also expects to achieve an operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025. BioCryst plans to reduce the size of its R&D organization and accelerate its timeline to profitability. The company will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. For more information, visit www.biocryst.com or follow BioCryst on LinkedIn.



Read more: BioCryst Announces Preliminary Full Year 2023 ORLADEYO®